Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab - PubMed
3 hours ago
- #lenvatinib
- #hepatocellular carcinoma
- #second-line therapy
- Atezolizumab plus bevacizumab (Ate+Bev) is a first-line therapy for unresectable hepatocellular carcinoma (HCC), but some patients experience early disease progression.
- The study retrospectively analyzed 36 patients with unresectable HCC who received lenvatinib after failure of first-line Ate+Bev.
- Patients were stratified by early progressive disease (PD), defined as radiologic progression at the 6-week assessment after starting Ate+Bev.
- Objective response rate (ORR) and disease control rate (DCR) were comparable between patients with and without early PD.
- Median progression-free survival (PFS) was similar between groups (5.2 months vs. 6.1 months).
- Early PD was not significantly associated with PFS or overall survival (OS) in multivariate analyses.
- Child-Pugh class A was independently associated with improved OS.
- Lenvatinib showed comparable antitumor activity and survival outcomes, even in patients with early PD on Ate+Bev.
- The findings support lenvatinib as a viable second-line option regardless of early Ate+Bev response, especially in patients with preserved liver function.